Dawnrays Pharmaceutical is a Hong Kong-based pharmaceutical enterprise, established in 1995 with the main operations in Suzhou, Jiangsu Province. Since July 2003, Dawnrays Pharmaceutical (Holdings) Ltd. has been listed on the Main Board of Hong Kong Stock Exchange Market.

The Group is engaged in the development, manufacturing and the sale of cephalosporin antibiotics, and various system specific medicines (generic drugs). The product range also covers various drug formulations, including bulk medicine, powder for injection, tablets, capsules, granules and midbody. It is one of the few third generation cephalosporin manufacturers in China that are adopting a comprehensive vertically integrated production process.

Dawnrays is equipped with advanced production process and techniques, especially its well-known advanced technology of solvent crystallization. In terms of our costs control, technologies capabilities, sales and distribution network, products qualities and the product prices, Dawnrays is more competent than all other enterprises in the industry. The cephalosporin bulk medicine and powder for injection form have been considered dominating the leading positions in China market since 2003. The Group will launch the fourth generation cephalosporin to the market by end 2005. With our 12 newly operated production lines and the newly constructed production plant, Dawnrays has boosted its production capacity of cephalosporin bulk medicine to 800 tons/year, and it is expected to become the biggest producer in China market.